ReCor's updated renal denervation system OK’d in Europe

| January 25, 2013 | Cardiovascular Business | Vascular & Endovascular

ReCor Medical's updated PARADISE (Percutaneous Renal Denervation) system has received CE Mark in Europe for treating resistant high blood pressure.

The 6 Fr over-the-wire ultrasound renal denervation device is designed to offer ultrasound therapy to reduce high blood pressure in treatment-resistant hypertension patients. The treatment parameters of Gen 2 have been enhanced to reduce energy delivery to 30 seconds by maximizing cooling of the endothelium and treating the nerves circumferentially.

The Gen 1 PARADISE system previously received CE Mark one year ago. It is the only CE-Marked system for renal denervation that is based on ultrasound, not radiofrequency energy, according to Menlo Park, Calif.-based ReCor, which developed the ultrasound system.

PARADISE is not currently available for clinical evaluation or sale in the U.S.

Around the web

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business

U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

Radiology Business

Tariffs not enough to make Siemens Healthineers move production or raise prices—yet

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.

ReCor's updated renal denervation system OK’d in Europe

Related Content

Around the web